Long-term follow-up of depression in psychiatric care
5 Years Follow-up of the Study: "Pharmacogenetics in Depressed Patients With Specific Focus on Difficult-to-treat Depresssion, Suicide Attempt and CYP2D6"
Region Skane · NCT07078227
This project will follow 415 people with difficult-to-treat depression who were previously studied to see how their symptoms and treatment outcomes change over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 415 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Skane (other) |
| Locations | 2 sites (Lund and 1 other locations) |
| Trial ID | NCT07078227 on ClinicalTrials.gov |
What this trial studies
Researchers will re-contact a cohort of 415 patients recruited between 2012 and 2021 who had detailed diagnostic interviews and were genotyped for CYP2D6 and CYP2C19. No new treatments are given; the team will extract clinical data from medical records and national registers for a five-year period after the original participation. Stored blood samples in a biobank allow future biomarker analyses linked to prognosis. The aim is to identify clinical and genetic predictors of long-term course and treatment outcomes in difficult-to-treat depression.
Who should consider this trial
Good fit: Ideal candidates are people who participated in the original pharmacogenetics study of difficult-to-treat depression and consent to follow-up via medical records and register linkage.
Not a fit: People who were not part of the original cohort or who do not consent to record access will not be included and therefore will not benefit from this follow-up.
Why it matters
Potential benefit: If successful, the findings could help clinicians predict who is more likely to recover or relapse and tailor medication choices based on clinical and genetic markers.
How similar studies have performed: Previous long-term observational cohorts and pharmacogenetic studies have yielded useful, mostly incremental insights into prognosis and medication response but have not produced definitive treatment algorithms.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Participation in the study "Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6" Exclusion Criteria: Not wanting to participate in the follow-up study
Where this trial is running
Lund and 1 other locations
- Psychiatry Reserach Unit — Lund, Sweden (ACTIVE_NOT_RECRUITING)
- Research Unit, Office of Psychiatricy, habilitation and technical aid — Lund, Sweden (RECRUITING)
Study contacts
- Study coordinator: Marie Asp, MD, PhD
- Email: marie.asp@skane.se
- Phone: +46702731013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Depression, Psychiatric Diagnosis, Personality Disorders, Suicide, Attempted, CYP2D6 Polymorphism, Anhedonia